Evidence map›Paper›PMID 34362430›Full record

ArticleGenome medicine2021

Recombination and lineage-specific mutations linked to the emergence of SARS-CoV-2.

Juan Ángel Patiño-Galindo, Ioan Filip, Ratul Chowdhury, Costas D Maranas, Peter K Sorger, Mohammed AlQuraishi, Raul Rabadan

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. virDTL: Viral Recombination Analysis Through Phylogenetic Reconciliation and Its Application to Sarbecoviruses and SARS-CoV-2.Journal of computational biology : a journal of computational molecular cell biology · 2023
    Article
  13. Article
  14. Human SARS-CoV-2 has evolved to increase U content and reduce genome size.International journal of biological macromolecules · 2022
    Article
  15. Review
  16. Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time.Journal of the Pediatric Infectious Diseases Society · 2021
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Juan Ángel Patiño-Galindo *Program for Mathematical Genomics, Columbia University, New York, NY, USA.
Ioan Filip *Program for Mathematical Genomics, Columbia University, New York, NY, USA.
Ratul ChowdhuryDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.
Costas D MaranasDepartment of Chemical Engineering, The Pennsylvania State University, University Park, PA, USA.
Peter K SorgerDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.
Mohammed AlQuraishiDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.
Raul RabadanProgram for Mathematical Genomics, Columbia University, New York, NY, USA. rr2579@cumc.columbia.edu.
Columbia University · USCenter for Systems Biology · USHarvard University · USPennsylvania State University · US

Funding

Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SHARPE, ARLENE H. · 2018 to 2022
$10.8M
Uncovering Evolutionary History using the Topology of Genomic Data with Applications to HIVR01GM117591 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RABADAN, RAUL · 2015 to 2018
$1.3M
Defense Advanced Research Projects Agency W911NF-14-1-0397NCI NIH HHS U54 CA225088NIGMS NIH HHS R01 GM117591NIH HHS R01 GM117591NIH HHS U54-CA225088
6 · The paper itself

Abstract

backgroundThe emergence of SARS-CoV-2 underscores the need to better understand the evolutionary processes that drive the emergence and adaptation of zoonotic viruses in humans. In the betacoronavirus genus, which also includes SARS-CoV and MERS-CoV, recombination frequently encompasses the receptor binding domain (RBD) of the Spike protein, which is responsible for viral binding to host cell receptors. In this work, we reconstruct the evolutionary events that have accompanied the emergence of SARS-CoV-2, with a special emphasis on the RBD and its adaptation for binding to its receptor, human ACE2.

methodsBy means of phylogenetic and recombination analyses, we found evidence of a recombination event in the RBD involving ancestral linages to both SARS-CoV and SARS-CoV-2. We then assessed the effect of this recombination at protein level by reconstructing the RBD of the closest ancestors to SARS-CoV-2, SARS-CoV, and other Sarbecoviruses, including the most recent common ancestor of the recombining clade. The resulting information was used to measure and compare, in silico, their ACE2-binding affinities using the physics-based trRosetta algorithm.

resultsWe show that, through an ancestral recombination event, SARS-CoV and SARS-CoV-2 share an RBD sequence that includes two insertions (positions 432-436 and 460-472), as well as the variants 427N and 436Y. Both 427N and 436Y belong to a helix that interacts directly with the human ACE2 (hACE2) receptor. Reconstruction of ancestral states, combined with protein-binding affinity analyses, suggests that the recombination event involving ancestral strains of SARS-CoV and SARS-CoV-2 led to an increased affinity for hACE2 binding and that alleles 427N and 436Y significantly enhanced affinity as well.

conclusionsWe report an ancestral recombination event affecting the RBD of both SARS-CoV and SARS-CoV-2 that was associated with an increased binding affinity to hACE2. Structural modeling indicates that ancestors of SARS-CoV-2 may have acquired the ability to infect humans decades ago. The binding affinity with the human receptor would have been subsequently boosted in SARS-CoV and SARS-CoV-2 through further mutations in RBD.

Indexed as

Evolution, MolecularRecombination, GeneticAngiotensin-Converting Enzyme 2AnimalsCOVID-19HumansSARS-CoV-2Spike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Receptor binding affinityRecombinationSARS-CoV-2Zoonosis

Identifiers

PMID34362430
PMCPMC8343217
OpenAlexW3191027841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.